Defibrotide for severe veno-occlusive disease following stem cell transplant

From 1 April 2021, defibrotide is recommended to be available as a treatment option through routine commissioning for severe veno-occlusive disease following stem cell transplant within the criteria set out in this document.

Source:

NHS England